NCT02677038View on ClinicalTrials.gov

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 11, 2016

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions
Metastatic Pancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v6 and v7
Interventions
DRUG

Olaparib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER